
Neumic Therapeutics Ltd
New Zealand · Biotech & life sciences · Undetermined
BILIX
South Korea · Biotech & life sciences · Series A
Compatibility /100
30/100
Low potentialWhy talk
- Neumic Therapeutics Ltd likely needs funding — BILIX (South Korea, Series A, $13.3M raised) can offer investor introductions (inferred from public profile).
- Same sector (Biotech & life sciences): peer learning on regulation, pricing and investors; Neumic Therapeutics Ltd works on University therapeutics spin-off (presumed neuroscience), BILIX on Drug for acute kidney injury.
- BILIX is based in South Korea (Asia): a landing pad on another continent, both ways.
Score anatomy
Each segment is what one dimension adds, out of 100.
Score by goal
Dimension by dimension
Needs ↔ offers
12.5 / 25 pts
BILIX can help Neumic Therapeutics Ltd.
- Neumic Therapeutics Ltd likely needs funding — BILIX (South Korea, Series A, $13.3M raised) can offer investor introductions (inferred from public profile).
Market bridge
3.8 / 15 pts
Distant markets.
- BILIX is based in South Korea (Asia): a landing pad on another continent, both ways.
Customer potential
0.0 / 40 pts
Neither side has a product on the market yet.
No supporting signal in the records.
Sector synergy
11.3 / 15 pts
Same sector: peers.
- Same sector (Biotech & life sciences): peer learning on regulation, pricing and investors; Neumic Therapeutics Ltd works on University therapeutics spin-off (presumed neuroscience), BILIX on Drug for acute kidney injury.
Stage complementarity
2.3 / 5 pts
Weak stage signal.
- BILIX has raised about $13.3M — investor introductions are realistic.
- Stage not comparable (Undetermined / Series A).
How the score works
Each dimension gives a value between 0 and 1, multiplied by its weight; the compatibility is the sum (0–100). Weights for “Customers”: Needs ↔ offers 25, Market bridge 15, Customer potential 40, Sector synergy 15, Stage complementarity 5. Declared needs and offers count fully; when a startup has declared nothing, a few needs/offers are inferred from its public profile (for example, no known traction ⇒ needs customers) and count at half value.
Potential blends compatibility (65%) with the mean global score of both startups (35%): 34/100 — high from 50, medium from 36.